Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors by van Etten, B et al.
Short Communication
Impaired neutralising antibody formation and high transduction
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Local adenoviral gene transfer can be performed by means of isolated hepatic perfusion (IHP). This methodology is a very effective
and safe way to deliver adenoviral vectors. We studied the immune response after IHP. A decreased neutralising antibody formation
was observed, offering possibilities for further research in the field of gene therapy in isolated perfusion settings.
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The main reason for failure of adenoviral gene delivery is
insufficient transduction efficacy in vivo. A method, which
improves in vivo efficacy, is locoregional administration. Pre-
viously, we and others demonstrated successful transduction and
subsequent tumour response after isolated limb perfusion (ILP)
and isolated hepatic perfusion (IHP) (de Roos et al, 1997, 2000; de
Wilt et al, 2001; van Etten et al, 2002).
Adenoviral mediated gene transfer results in transient gene
expression. Loss of the therapeutic gene requires readministration
to achieve prolonged gene expression, which however is precluded
by formation of neutralising antibodies (Yang et al, 1994; Kaplan
et al, 1997). Since IHP is a technique with minimal systemic
exposure and washout possibilities after the perfusion, immune
response after adenoviral treatment may be impaired.
We performed IHP in rats with a recombinant adenoviral vector
and investigated the production of neutralising antibodies and
leukocytes compared to systemic intravenous (i.v.) treatment.
MATERIALS AND METHODS
Animals
Male inbred immunocompetent WAG/RIJ rats, weighing 250–
300g (Harlan-CPB, The Netherlands) were used. The rats were fed
a standard laboratory diet and were housed under standard
conditions of light and accommodation. The ethical committee for
animal research of the Erasmus University Medical Center
approved the protocol. The experimental protocols adhered to
the rules outlined in the Dutch Animal Experimentation Act of
1977 and the published UKCCCR Guidelines for the Welfare of
Animals in Experimental Neoplasia (Workman et al, 1998).
Recombinant adenovirus construct
The viral constructs were provided by Aventis-Pharma (Vitry-sur-
Seine, France) and are described previously by us in detail (van
Etten et al, 2002). AV1.0CMV is a recombinant replication-
deficient adenovirus vector. AV1.0CMV.LacZ expresses the
Escherichia coli derived b-galactosidase protein that can be
detected by X-gal histochemistry.
Routes of administration
Isolated hepatic perfusion We have described the rat isolated
liver perfusion model in detail earlier (van IJken et al, 2000). Rats
were perfused for 10min with oxygenated and heated (38–391C)
colloid fluid (Haemaccel, Behring Pharma, Amsterdam, Nether-
lands) with 1.0 10
11 virus particles (vp). This dose was previously
determined as the maximum tolerated dose (MTD). Afterwards, a
washout procedure was performed to remove all nonbound viruses
by perfusing with 10ml Haemaccel.
Intravenous injection A volume of 200ml of PBS containing
2.5 10
11 vp (MTD) was slowly injected into the penile vein.
Blood and tissue sampling
Blood samples were taken via the tail vein at day 0, 3, 6, 9,16, 23,
and 30 after treatment. Serum was collected after centrifugation
(16000 g) and stored at  801C until further analysis. At 24h
after treatment animals were killed. Liver was taken out and snap
frozen in liquid nitrogen. Cryosections of tissue samples were
stained according to the X-gal staining protocol (van Etten et al,
2002).
Measurement of neutralising antibodies
Adenovirus type 5 specific neutralising antibodies were measured
by the virus neutralisation (VN) test as previously described
(Schrader and Wigand, 1981; De Jong et al, 1999). The presence of
cytopathic effects of Hep 2 cells caused by the virus was scored Received 26 May 2004; revised 22 July 2004; accepted 29 July 2004
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sunder the microscope. Neutralising antibody titres were expressed
as the highest serum dilution showing no cytopathological effects.
Measurement of leukocyte count, liver and renal functions
Leukocyte numerations were determined with a microcell counter
(Sysmex; Kyoto, Japan). Liver functions (alkaline phosphatase,
alaline aminotransferase, aspartate aminotransferase, total bilir-
ubin and g-glutamyl transpeptidase) and renal functions (creatinin
and urea) were measured by spectophotometric analysis (ELAN-
analyzer; Eppendorf-Merck, Hamburg, Germany).
Statistical analysis
Results were evaluated for statistical significance with the
Kruskal–Wallis and Mann–Whitney U tests with SPSSv10.0 for
Windows 2000. A significance level of Po0.05 was used.
RESULTS
We observed augmented transfection of cells after isolated
perfusion (n¼3) (transduction efficacy of 80–90%) compared to
systemic therapy (n¼3) (transduction efficacy around 5%)
(Figure 1).
Antibody titres after IHP (n¼5) were significantly lower
compared to i.v. (n¼5) from day 3 up to day 23 (Figure 2). On
day 6 after treatment a mean peak titre could be measured: 352
after i.v. injection vs 27 after IHP (P¼0.03). During follow-up,
performed up to 30 days after treatment the levels decreased and
were equalised approximately as from day 23.
Leukocyte count was determined at day 6 after treatment.
Numerations of leukocytes (mean values of three animals7s.d.)
were significantly higher after i.v. (2.16 10
1070.19) compared to
IHP (1.18 10
1070.45) or the untreated control group
(1.15 10
1070.16), whereas leukocyte count after IHP was not
increased compared to control values (i.v. vs IHP: Pp0.05, i.v. vs
control: Pp0.05). The increased leukocyte count following i.v.
administration correlates directly with the rise of titres measured
after i.v. treatment.
No severe hepatic or renal toxicity could be detected in the i.v.
or IHP group after treatment. Levels of toxicity parameters
measured in sera varied in a range of þ and  25% of the control
values (data not shown). After i.v. injection, no weight loss was
observed. Following IHP a maximum transient weight loss of 10%
was observed, which could not be related to the viral vector as
similar weight loss was observed upon sham IHP.
DISCUSSION
Isolated hepatic perfusion is a more effective and safe method to
deliver adenoviral vectors towards liver or tumour cells compared
to i.v. injection (de Roos et al, 1997; van Etten et al, 2002). A
transduction efficacy up to 45% of hepatocytes by means of IHP
combined with a chelating agent has been described (de Roos et al,
1997). Here we demonstrate that this highly selective delivery
method can result in even higher transduction rates and,
importantly, is accompanied by an impaired neutralising antibody
formation and leukocyte proliferation. Several studies have been
conducted to influence immune response upon adenoviral gene
therapy, including incorporation of immunosuppressive genes into
the vector or manipulation of the immune system during
administration (Qin et al, 1997; Nakagawa et al, 1998; Kuzmin
et al, 2001). To our knowledge this is the first report demonstrating
an impaired immune response using isolated perfusion methodol-
ogy with a ‘regular’ adenoviral vector in an immunocompetent
animal model.
Figure 1 X-gal staining of liver tissue after treatment with AV1.0CMV.
LacZ. (A) After IHP, estimated transduction of 80–90%. (B) After i.v.
injection, estimated transduction of about 5%. Representative pictures of
liver tissue samples of three animals per treatment.
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Figure 2 Neutralising antibody titre after i.v. (E) or IHP (m) with
AV1.0CMV determined as described in Materials and methods section.
Antibody titres after IHP were significantly lower compared to i.v. from day
3 up to day 23 (Pp0.05). On day 6 after treatment a mean peak titre could
be measured: 352 after i.v. injection vs. 27 after IHP (P¼0.03). Mean values
of five animals7s.d. are shown.
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sThe liver is known for its ability to induce immune tolerance
(Calne, 2000). Both in patients and animal models host-to-graft
tolerance was observed (Kamada et al, 1981; Mazariegos et al,
1997). Liver sinusoidal endothelial cells (LSECs), which clear the
antigen from the blood can function as an antigen-presenting cell
(Limmer et al, 2000). Naı ¨ve T cells, which are activated by the
LSECs, do not differentiate into effector T cells thereby inducing
antigen-specific T cell tolerance (Knolle and Limmer, 2001). This
mechanism might play a role in the lesser immune response we
observed.
It is known that the height of neutralising antibodies titres is
correlated with the dose of virus administrated (Yang et al, 1996).
Since most circulating viruses are washed away at the end the
perfusion, only a relative low viral load is left behind in the liver.
Worgall et al (1997) demonstrated that the acute innate immune
mechanism eliminated 90% of the circulating adenoviral vectors
within 24h. So, if hardly any circulating viruses are left after IHP
and the majority is cleared rapidly, only an extremely low amount
of viruses can induce the humoral immune response, likely
resulting in low neutralising antibody production.
Retrograde infusion of adenoviruses in the common bile duct of
mice resulted in increased hepatic restricted gene transfer,
combined with lower neutralising antibody titres (Peeters et al,
1996). It has been reported that the route of administration
strongly determines the humoral immunity to the transgene in
experiments with adeno-associated virus vectors in mice. Delivery
via the hepatic artery resulted in higher transgene expression and
an absent immune response to the transgene product (Nathwani
et al, 2001). These results and our current findings suggest that
loco-regional liver directed gene therapy offers advantages at gene
transfer efficacy level as well as at immune response level. We
recently performed pilot experiments with repeated administra-
tion. Primary adenovirus treatment by IHP followed by i.v.
challenge 30 days later. These preliminary data showed no
advantage with respect to transduction efficacy after the i.v.
administration. Since repeated IHP in rats is not possible due to
technical reasons we cannot provide data on this issue at this
moment. In pigs we previously developed leakage free and
potentially repeatable balloon catheter based IHP technique (van
IJken et al, 1998), offering possibilities for future experiments with
repeated IHP.
In conclusion, our findings are a strong argument for further
research on delivery of viral vectors in isolated perfusion settings
(limb, kidney, lung, liver).
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